Home › Funds › Foresite Capital Management V, LLC › LYEL
Foresite Capital Management V, LLC position in LYEL
LYELL IMMUNOPHARMA INC · Health Care
Foresite Capital Management V, LLC reported holding 476,386 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$6.7M, representing 1.85% of its reported portfolio and ranking #8 among its reported holdings. Foresite Capital Management V, LLC has disclosed LYEL holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Foresite Capital Management V, LLC's LYEL position evolved
Foresite Capital Management V, LLC first disclosed a stake in LYEL in Q4 2024 at 8,133,047 shares (US$5.2M). The position peaked in Q4 2025 at 477,078 shares, worth US$14.7M. Across 7 filings, Foresite Capital Management V, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 476,386 shares valued at US$6.7M. Notable position changes include a 95% trim in Q2 2025 (shares rose 84% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 8.13M | $5.21M | New |
| Q1 2025 | 8.13M | $4.38M | Hold |
| Q2 2025 | 406.65K | $3.59M | Reduce |
| Q3 2025 | 477.08K | $7.75M | Add |
| Q4 2025 | 477.08K | $14.68M | Hold |
| Q1 2026 | 477.08K | $9.57M | Hold |
| Q2 2026 | 476.39K | $6.69M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LYEL and 13F data
LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 31 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$21.3M), Orland Properties Ltd (US$10.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LYEL
- ARCH Venture Management, LLC 3.25M sh · $45.53M · Q2 2026
- GSK plc 1.51M sh · $21.25M · Q2 2026
- Orland Properties Ltd 754.70K sh · $10.60M · Q2 2026
- Decheng Capital LLC 692.05K sh · $9.72M · Q2 2026
- Almitas Capital LLC 581.41K sh · $8.17M · Q2 2026
- Opaleye Management Inc. 344.02K sh · $4.83M · Q2 2026
- venBio Partners LLC 337.70K sh · $4.74M · Q2 2026
- Alphabet Inc. 293.26K sh · $4.12M · Q2 2026
- HSG Holding Ltd 152.30K sh · $2.14M · Q2 2026
- Velan Capital Investment Management LP 105.00K sh · $1.48M · Q2 2026
- MIC Capital Management UK LLP 87.03K sh · $1.22M · Q2 2026
More on Foresite Capital Management V, LLC
FAQ
How long has Foresite Capital Management V, LLC held LYEL?
Foresite Capital Management V, LLC has disclosed LYEL holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Foresite Capital Management V, LLC's current position in LYEL?
As of Q2 2026, Foresite Capital Management V, LLC holds 476.39K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $6.69M, representing 1.85% of its reported portfolio and ranking #8.
Has Foresite Capital Management V, LLC been buying or selling LYEL?
In the latest 13F filing (Q2 2026), Foresite Capital Management V, LLC held unchanged its position in LYEL. The position peaked in Q4 2025 at 477.08K shares.
Which other funds hold LYEL?
Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Orland Properties Ltd, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.